Products
Tools
Education
$16.93
$16.00
$29.35
$7.89
$950.3M
76.62%
This is a preview of the full version of Prosperse
Cullinan Therapeutics presented positive updated data from its pivotal Phase 2b study of zipalertinib in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on prior amivantamab treatment. The data showed a consistent objective response rate of 40% and ...
N/A
Sep 14, 2024
Date: Oct 25, 2024
Date: Oct 24, 2024